Wegovy
- All
- News
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Weight Loss Pill Wegovy Now Available On Amazon Pharmacy In The U.S.
Amazon Pharmacy maintains the requirement for a valid prescription as the central safeguard separating evidence-based medical therapy from consumer health products.
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Ozempic Injection Price In India: How Affordable Is It For Diabetes And Weight Loss?
Ozempic, a once-weekly semaglutide injection for type-2 diabetes, has debuted in India with pricing starting at roughly Rs 2,200 per week.
-
Ozempic Launched In India: Doctors Welcome New Diabetes Drug, Warn Against Misuse For Weight Loss
Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.
-
"Unusual" Side Effect of Ozempic-Like Drugs Challenges Doctors: Research
GLP-1 medications, Ozempic and Wegovy, may disrupt cancer imaging and its diagnosis, new research has revealed.
-
Ozempic Launched In India: 14 Facts About The Diabetes, Weight Loss Drug
Semaglutide (Ozempic), a once-weekly injectable already approved globally, has now been launched in India for type 2 diabetes.
-
Ozempic Cleared For Use In India: Pros, Cons And Prices
Ozempic is the trade name for semaglutide, a once-weekly injectable medicine that belongs to the class called GLP-1 receptor agonists. A higher-dose semaglutide better known as Wegovy is licensed for chronic weight management.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
What Happens To Your Body When You Stop Taking Drugs Like Ozempic? Study Explains
The study found that GLP-1 medications, in particular, showed significant weight regain after treatment discontinuation.
-
Wegovy And Mounjaro For Weight Loss Are In, But India Wants A No-Drug Obesity Fix
A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications
-
Novo Nordisk Launches Weight-Loss Drug 'Wegovy' In India
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy as a once-a-week injection in India.
-
UK Warns Women About 'Skinny Jabs' If Trying To Get Pregnant
The UK's medicine regulator warned on Thursday against taking "skinny jabs" for weight loss if trying to get pregnant or while breastfeeding because of their unknown effects on babies.
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
Weight Loss Pill Wegovy Now Available On Amazon Pharmacy In The U.S.
Amazon Pharmacy maintains the requirement for a valid prescription as the central safeguard separating evidence-based medical therapy from consumer health products.
-
Ozempic Maker's Weight Loss Pill Gets Key Clearance In US, Launch Days Away
The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on access, cost and regulation for Indians.
-
Popular Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks, Study Finds
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more than 94,000 participants.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Ozempic Injection Price In India: How Affordable Is It For Diabetes And Weight Loss?
Ozempic, a once-weekly semaglutide injection for type-2 diabetes, has debuted in India with pricing starting at roughly Rs 2,200 per week.
-
Ozempic Launched In India: Doctors Welcome New Diabetes Drug, Warn Against Misuse For Weight Loss
Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.
-
"Unusual" Side Effect of Ozempic-Like Drugs Challenges Doctors: Research
GLP-1 medications, Ozempic and Wegovy, may disrupt cancer imaging and its diagnosis, new research has revealed.
-
Ozempic Launched In India: 14 Facts About The Diabetes, Weight Loss Drug
Semaglutide (Ozempic), a once-weekly injectable already approved globally, has now been launched in India for type 2 diabetes.
-
Ozempic Cleared For Use In India: Pros, Cons And Prices
Ozempic is the trade name for semaglutide, a once-weekly injectable medicine that belongs to the class called GLP-1 receptor agonists. A higher-dose semaglutide better known as Wegovy is licensed for chronic weight management.
-
WHO Adds Key Diabetes, Weight-Loss Drugs To Essential Medicines List
The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for type 2 diabetes with obesity or comorbidities.
-
What Happens To Your Body When You Stop Taking Drugs Like Ozempic? Study Explains
The study found that GLP-1 medications, in particular, showed significant weight regain after treatment discontinuation.
-
Wegovy And Mounjaro For Weight Loss Are In, But India Wants A No-Drug Obesity Fix
A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications
-
Novo Nordisk Launches Weight-Loss Drug 'Wegovy' In India
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy as a once-a-week injection in India.
-
UK Warns Women About 'Skinny Jabs' If Trying To Get Pregnant
The UK's medicine regulator warned on Thursday against taking "skinny jabs" for weight loss if trying to get pregnant or while breastfeeding because of their unknown effects on babies.
